Taro Provides Results for September 30, 2017

Business Wire India

November 7, 2017-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) provided unaudited financial results for the three and six months ended September 30, 2017.

 

Quarter ended September 30, 2017 Highlights - compared to September 30, 2016

 

• Net sales of $169.9 million decreased $58.9 million, the result of continuing increased competition and the challenging pricing environment; despite a slight increase in volumes.
• Gross profit of $125.1 million decreased $52.2 million, and as a percentage of net sales, was 73.6% compared to 77.5%.
• Research and development (R&D) expenses increased $3.2 million to $18.0 million.
• Selling, marketing, general and administrative expenses (SG&A) decreased $2.5 million to $18.3 million.
• Operating income of $88.8 million decreased $52.8 million, or 52.3% of net sales compared to 61.9%.
• Net Income was unfavorably impacted by a $46.0 million fluctuation in foreign exchange (FX) from income of $13.4 million in 2016 to an expense of $32.6 million in 2017, principally the result of the strength of the Canadian dollar vs. U.S. dollar.
• Tax expense of $6.9 million decreased $28.7 million; with the effective tax rate of 11.5% compared to 22.3%.
• Net income attributable to Taro was $52.4 million compared to $123.7 million, a $71.3 million decrease, resulting in diluted earnings per share of $1.30 compared to $3.00.

Six Months ended September 30, 2017 Highlights - compared to September 30, 2016

 

• Net sales of $331.2 million decreased $131.3 million, the result of continuing increased competition and the challenging pricing environment; despite an increase in volumes.
• Gross profit of $241.7 million decreased $118.4 million, and as a percentage of net sales, was 73.0% compared to 77.8%.
• R&D expenses of $32.7 million remained in line with prior year expenses with all of our activities, including clinical studies, proceeding according to plan.
• SG&A remained relatively flat at $42.6 million.
• Operating income of $166.4 million decreased $117.8 million, or 50.2% of net sales compared to 61.4%.
• Net Income was unfavorably impacted by a $59.7 million fluctuation in FX from income of $7.5 million in 2016 to an expense of $52.2 million in 2017, principally the result of the strength of the Canadian dollar vs. U.S. dollar.
• Tax expense of $16.9 million decreased $49.1 million; with the effective tax rate of 13.6% compared to 22.0%.
• Net income attributable to Taro was $106.9 million compared to $233.6 million, a $126.7 million decrease, resulting in diluted earnings per share of $2.65 compared to $5.59.

Mr. Uday Baldota, Taro’s CEO stated, “We continue to navigate the current industry challenges − increased competitive intensity, pressures from buying consortiums, and higher ANDA approval rates from the FDA. In order to deliver long-term performance and a quality pipeline of products, we continue our investment in R&D. In addition, given our strong cash position, we will continue to explore and evaluate business development opportunities that meet both our operational and financial targets.”

 

Cash Flow and Balance Sheet Highlights

 

• Cash flow provided by operations for the six months ended September 30, 2017, was $138.7 million compared to $192.7 million for the six months ended September 30, 2016.
• As of September 30, 2017, cash, including short-term bank deposits and marketable securities (both short and long-term), increased $83.3 million to $1.5 billion from March 31, 2017. Cash reflects the $40.4 million impact from the Company’s share repurchases.

FDA Approvals and Filings

 

The Company recently received approval from the U.S. Food and Drug Administration (“FDA”) for the Abbreviated New Drug Application (“ANDA”) Dapsone Gel, 5%. The Company currently has a total of thirty-two ANDAs awaiting FDA approval, including five tentative approvals.

 

Company’s Office Holders Compensation Policy

 

On February 9, 2017, the Taro Board of Directors (the “Board”), based on the recommendation of the Compensation Committee of the Board, and in accordance with Section 276A(c) of the Companies Law, approved a renewed version of the Company’s Office Holders Compensation Policy (the “Policy”). Such approval made the Policy effective until it could be reconsidered by Taro’s shareholders at the 2017 Annual General Meeting of Shareholders.

 

On November 7, 2017, the Board elected, with Taro’s Compensation Committee recommendation, to extend its approval of the Policy until the 2018 Annual General Meeting of Shareholders in order to permit additional time to address feedback from various stakeholders.

 

Share Repurchase Program - Returning Capital to Shareholders

 

On November 23, 2016, the Company announced that its Board of Directors approved a $250 million share repurchase of ordinary shares. Under this authorization, repurchases may be made from time to time at the Company’s discretion, based on ongoing assessments of the capital needs of the business, the market price of its stock, and general market conditions. The repurchase authorization enables the Company to purchase its ordinary shares from time to time through open market purchases, negotiated transactions or other means, including 10b5-1 trading plans in accordance with applicable securities laws or other restrictions. During the current fiscal year, through October 31, 2017, the Company has repurchased 410,664 shares at an average price of $103.79. Under this program, in total, the Company has repurchased 929,629 shares, with $153.1 million remaining under the authorization. On November 7, 2017, the Board extended the share repurchase program for one year.

 

Earnings Call(8:00 am EST, November 8, 2017)

 

As previously announced, the Company will host an earnings call at 8:00 am EST on Wednesday, November 8, 2017, where senior management will discuss the Company’s performance and answer questions from participants. This call will be accessible through an audio dial-in and a web-cast. Audio conference participants can dial-in on the numbers below:

 

• Participant Toll-Free Dial-In Number: +1 (844) 421-0601 ID: 4298818
• Participant International Dial-In Number: +1 (716) 247-5800 ID: 4298818
• Audio web-cast: Details are provided on our website, www.taro.com

To participate in the audio call, please dial the numbers provided above five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. The transcript of the event will be available on the Company’s website at www.taro.com.

 

The Company cautions that the foregoing financial information is presented on an unaudited basis and is subject to change.

 

About Taro

 

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

 

SAFE HARBOR STATEMENT

 

The unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments necessary to present fairly the financial condition and results of operations of the Company.The unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 20-F, as filed with the SEC.

 

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements with respect to the Company’s financial performance, availability of financial information, and estimates of financial results and information for fiscal year 2018.Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained.Factors that could cause actual results to differ include general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company’s SEC reports, including its Annual Reports on Form 20-F.Forward-looking statements are applicable only as of the date on which they are made.The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

 

**Financial Tables Follow**

 

TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(U.S. dollars in thousands, except share data)
				Quarter Ended										Six Months Ended
				September 30,										September 30,
				2017					2016					2017					2016
Sales, net				$	169,915				$	228,794				$	331,236				$	462,578
Cost of sales					44,795					51,428					89,573					102,313
Impairment					—					76					—					184
Gross profit					125,120					177,290					241,663					360,081
Operating Expenses:
Research and development					17,995					14,845					32,653					32,765
Selling, marketing, general and administrative					18,342					20,886					42,591					43,137
Operating income					88,783					141,559					166,419					284,179
Financial (income) expense, net:
Interest and other financial income					(4,602	)				(3,546	)				(9,078	)				(6,853	)
Foreign exchange expense (income)					32,583					(13,375	)				52,225					(7,465	)
Other (loss) gain, net					(1,310	)				1,054					808					1,457
Income before income taxes					59,492					159,534					124,080					299,954
Tax expense					6,864					35,558					16,851					65,984
Income from continuing operations					52,628					123,976					107,229					233,970
Net loss from discontinued operations attributable to Taro					(145	)				(76	)				(192	)				(177	)
Net income					52,483					123,900					107,037					233,793
Net income attributable to non-controlling interest					90					243					147					240
Net income attributable to Taro				$	52,393				$	123,657				$	106,890				$	233,553
Net income per ordinary share from continuing operations attributable to Taro:
Basic and Diluted				$	1.30				$	3.00				$	2.65				$	5.59
Net loss per ordinary share from discontinued operations attributable to Taro:
Basic and Diluted				$	(0.00	)	*		$	(0.00	)	*		$	(0.00	)	*		$	(0.00	)	*
Net income per ordinary share attributable to Taro:
Basic and Diluted				$	1.30				$	3.00				$	2.65				$	5.59
Weighted-average number of shares used to compute net income per share:
Basic and Diluted					40,315,991					41,300,387					40,402,257					41,832,592
* Amount is less than $0.01
May not foot due to rounding.

TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
				September 30,				March 31,
				2017				2017
ASSETS				(unaudited)				(audited)
CURRENT ASSETS:
Cash and cash equivalents				$	503,321			$	600,399
Short-term and current maturities of long-term bank deposits					556,121				782,813
Marketable securities					339,444				3,548
Accounts receivable and other:
Trade, net					201,710				203,924
Other receivables and prepaid expenses					176,298				266,280
Inventories					150,191				141,045
Long-term assets held for sale, net					—				1,015
TOTAL CURRENT ASSETS					1,927,085				1,999,024
Long-term deposits and marketable securities					141,887				70,685
Property, plant and equipment, net					187,937				180,085
Deferred income taxes					125,597				10,324
Other assets					31,311				29,635
TOTAL ASSETS				$	2,413,817			$	2,289,753
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables and other current liabilities				$	201,546			$	209,837
TOTAL CURRENT LIABILITIES					201,546				209,837
Deferred taxes and other long-term liabilities					4,770				6,110
TOTAL LIABILITIES					206,316				215,947
Taro shareholders' equity					2,201,042				2,067,494
Non-controlling interest					6,459				6,312
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY				$	2,413,817			$	2,289,753

TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(U.S. dollars in thousands)
				Six Months Ended September 30,
				2017					2016
Cash flows from operating activities:
Net income				$	107,037				$	233,793
Adjustments required to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					7,794					7,397
Impairment for long-lived assets					—					184
Realized loss (gain) on sale of marketable securities and long-lived assets					125					(5	)
Change in derivative instruments, net					(4,388	)				2,337
Effect of change in exchange rate on inter-company balances and bank deposits					61,564					(9,034	)
Deferred income taxes, net					15,813					(11,422	)
Decrease (increase) in trade receivables, net					2,866					(11,285	)
Increase in inventories, net					(5,986	)				(11,611	)
(Increase) decrease in other receivables, income tax receivable, prepaid expenses and other					(37,359	)				13,054
Decrease in trade, income tax, accrued expenses, and other payables					(7,339	)				(20,731	)
Income from marketable securities					(1,430	)				—
Net cash provided by operating activities					138,697					192,677
Cash flows from investing activities:
Purchase of plant, property & equipment, net					(11,809	)				(19,238	)
Investment in other intangible assets					(1,554	)				(22	)
Proceeds from short-term bank deposits					221,851					138,344
Proceeds from (investment in) long-term deposits and other assets					75,528